Drug Trial Radar · NCT05361655
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
Last checked: Nov 19, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,888
Actual
Start
Sep 1, 2021
Primary completion
Sep 1, 2021
Study completion Sep 1, 2021
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 5, 2022
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices.
Conditions
- Metastatic Breast Cancer
Interventions
Palbociclib + an aromatase inhibitorDrug
Palbociclib + an aromatase inhibitor therapy
Aromatase inhibitorDrug
Aromatase inhibitor therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in Postmenopausal Female or Male Participants With Metastatic Breast CancerTime frame: From index date to death due to any cause or censoring date of 30-Sep-2020 (approximately up to 68 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
10017
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.